Profile data is unavailable for this security.
About the company
Moderna, Inc. is a biotechnology company. The Company is focused on developing messenger ribonucleic acid (mRNA) therapeutics and vaccines. It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range spectrum of diseases. The Company's products include Spikevax, the Moderna COVID-19 vaccine (mRNA-1273), a bivalent vaccine targeting the BA.1 Omicron variant, combined with Spikevax (mRNA-1273.214), and bivalent vaccine targeting the BA.4/BA.5 Omicron variants combined with Spikevax (mRNA-1273.222). It has a development pipeline of 45 development candidates across its 48 development programs, of which 38 are in clinical studies.
- Revenue in USD (TTM)15.06bn
- Net income in USD4.78bn
- LocationModerna Inc200 Technology SqCambridge 02139-3578United StatesUSA
- Phone+1 (617) 714-6500
- Fax+1 (617) 583-1998
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|MRNA:NSQ since |
|OriCiro Genomics KK||Deal completed||04 Jan 2023||04 Jan 2023Deal completed||-29.82%||85.00m|